Literature DB >> 15780623

Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome.

Isao Momose1, Yoji Umezawa, Sehei Hirosawa, Hironobu Iinuma, Daishiro Ikeda.   

Abstract

Tyropeptin A, a new potent proteasome inhibitor, was produced by Kitasatospora sp. MK993-dF2. To enhance the inhibitory potency of tyropeptin A, we constructed the structural model of tyropeptin A bound to the site responsible for the chymotrypsin-like activity of mammalian 20S proteasome. Based on these modeling experiments, we designed and synthesized several derivatives of tyropeptin A. Among them, the most potent compound, TP-104, exhibited a 20-fold enhancement in its inhibitory potency compared to tyropeptin A. Additionally, TP-110 specifically inhibited the chymotrypsin-like activity, but did not inhibit the PGPH and the trypsin-like activities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780623     DOI: 10.1016/j.bmcl.2005.02.013

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites.

Authors:  Matthew Britton; Marcella M Lucas; Sondra L Downey; Michael Screen; Alexandre A Pletnev; Martijn Verdoes; Robert A Tokhunts; Omar Amir; Ayrton L Goddard; Philip M Pelphrey; Dennis L Wright; Herman S Overkleeft; Alexei F Kisselev
Journal:  Chem Biol       Date:  2009-12-24

2.  Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.

Authors:  Kyle A Totaro; Dominik Barthelme; Peter T Simpson; Robert T Sauer; Jason K Sello
Journal:  Bioorg Med Chem       Date:  2015-07-26       Impact factor: 3.641

3.  Molecular basis of the selectivity of the immunoproteasome catalytic subunit LMP2-specific inhibitor revealed by molecular modeling and dynamics simulations.

Authors:  Beilei Lei; Mohamed Diwan M Abdul Hameed; Adel Hamza; Marie Wehenkel; Jennifer L Muzyka; Xiao-Jun Yao; Kyung-Bo Kim; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-09-30       Impact factor: 2.991

4.  Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.

Authors:  David L Wilson; Isabel Meininger; Zack Strater; Stephanie Steiner; Frederick Tomlin; Julia Wu; Haya Jamali; Daniel Krappmann; Marion G Götz
Journal:  ACS Med Chem Lett       Date:  2016-01-15       Impact factor: 4.345

Review 5.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

6.  Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study.

Authors:  Siwei Zhang; Yawei Shi; Hongwei Jin; Zhenming Liu; Liangren Zhang; Lihe Zhang
Journal:  J Mol Model       Date:  2009-05-14       Impact factor: 1.810

Review 7.  Proteasome regulators: activators and inhibitors.

Authors:  Li Huang; Chin Ho Chen
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 8.  Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.

Authors:  Marianne E Maresh; Andres F Salazar-Chaparro; Darci J Trader
Journal:  Future Med Chem       Date:  2020-12-04       Impact factor: 3.808

9.  Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.

Authors:  Isao Momose; Hikaru Abe; Takumi Watanabe; Shun-ichi Ohba; Kanami Yamazaki; Shingo Dan; Takao Yamori; Tohru Masuda; Akio Nomoto
Journal:  Cancer Sci       Date:  2014-10-21       Impact factor: 6.716

10.  Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells.

Authors:  Carlos García-Echeverría
Journal:  Int J Pept Res Ther       Date:  2006-03-04       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.